Compare TG Therapeutics Inc (TGTX) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs VF Corp — how do they compare? TG Therapeutics Inc trades at $55.14 (market cap $8.16B), while VF Corp trades at $15 (market cap $5.71B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and VF Corp pays a 2.48% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and VF Corp for 65 Days on average.
| TGTX | VFC | |
|---|---|---|
Market Cap | $8.16B | $5.71B |
Volume | 1,735,121 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $21.55 |
52-Week Low | $26.94 | $12.62 |
Typical Hold Time | 16 Days | 65 Days |
Enterprise Value | $8.37B | $10.00B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
VFC trades at $15.00, up 4.31% today, with a bullish technical signal from moving averages and oscillators. The company reported mixed quarterly results, beating in Q4 2025 but missing in subsequent quarters, with revenue declining from $11.8B in 2022 to $9.5B in 2025. Analyst consensus is a 'Hold' with a $18.33 price target, representing 22% upside potential from current levels.
VFC faces execution challenges with Vans brand weakness offsetting strength in Outdoor segments, though valuation appears attractive with P/S of 0.61. Key risks include ongoing revenue declines, negative net income, and high debt levels. The stock offers potential upside if management's turnaround plan succeeds, but requires careful monitoring of quarterly execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
